This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HSIC or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
CONMED's (CNMD) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) third-quarter earnings reflect strong segmental performance.
Conmed (CNMD) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 3.90% and -2.51%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Conmed (CNMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain CONMED (CNMD) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Conmed (CNMD) Down 4.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HSIC vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
HSIC vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
CONMED's (CNMD) Q2 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
CONMED (CNMD) witnesses revenue uptick in both of its segments during Q2 despite continued pandemic-led business disruptions.
Conmed (CNMD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 14.52% and 2.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
LH vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Align Technology (ALGN) Launches New Features in iTero Family
by Zacks Equity Research
Align Technology's (ALGN) iTero Workflow 2.0 software and iTero Element 5D Imaging system auto-upload functionality to drive innovation in digital orthodontics and restorative dentistry.
Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Henry Schein (HSIC) Clinches HHS Deal for COVID-19 Supplies
by Zacks Equity Research
Henry Schein (HSIC) to extend effective inventory management and extensive logistical support for PPE and COVID related products within the spectrum of U.S. health care.
Medtronic (MDT) Diabetes Arm Secures Two Approvals in Europe
by Zacks Equity Research
These two latest innovations are likely to enable Medtronic (MDT) to offer the only pump that adjusts and corrects every five minutes with an infusion set that lasts twice as long.
Why Is Conmed (CNMD) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HSIC vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.
Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.
Henry Schein (HSIC) Q1 Earnings Top Estimates, '21 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q1 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.